INTRODUCTION: Moderate and high levels of anticardiolipin antibodies (aCL), especially in the setting of the antiphospholipid syndrome, are associated with adverse obstetric outcomes. However, the clinical relevance of low aCL levels (<40 MPL/GPL units) is still a matter of debate. The aim of the study was to evaluate obstetric outcomes in pregnancies with low immunoglobulin M (IgM) and/or immunoglobulin G (IgG) aCL positivity. The association between low aCL positivity and maternal baseline characteristics was also studied. MATERIAL AND METHODS: The retrospective monocentric cohort study of prospectively collected data involved a total 3047 singleton pregnancies that underwent the first-trimester screening involving an aCL test and delivered on site. Obstetric outcomes were compared between the low-titer aCL group (IgM ≥7 MPL units and <40 MPL units and/or IgG ≥10 GPL units and <40 GPL units) and the aCL negative group (IgM <7 MPL units and IgG <10 GPL units, reference group). In addition, obstetric outcomes were evaluated with regard to the antibody isotype: IgM-positive group (IgM <40 MPL units, IgG negative) and IgG-positive group (IgG <40 GPL units, IgM negative or <40 MPL units). RESULTS: Overall, the occurrence of pregnancy-related complications was significantly higher (27.91% vs. 19.32%, p = 0.034) in the low-titer aCL group. Concerning the antibody isotype, a higher rate of pregnancy-related complications was observed in the IgG-positive group (54.55% vs. 19.32%, p = 0.001), but not in the IgM-positive group (22.43% vs. 19.32%, p = 0.454). The stillbirth rate did not reach statistical significance. Low-titer aCL pregnancies were more frequently of advanced maternal age (p < 0.001), suffered from autoimmune diseases (p < 0.001), chronic hypertension (p = 0.040), and hereditary thrombophilia (p = 0.040). In addition, they had more often a positive history of stillbirth (p < 0.001), underwent conception via assisted reproductive technologies (p < 0.001), were administered low-dose aspirin (p < 0.001), low-molecular-weight heparin (p = 0.018) and immunomodulatory drugs (p < 0.001), and delivered earlier (p = 0.018). CONCLUSIONS: Even low aCL levels are associated with a higher incidence of pregnancy-related complications, but only in the case of IgG antibody isotype presence. Screening for aCL in the first trimester has some prognostic value, but further studies are needed to determine whether its potential implementation into routine clinical practice would improve antenatal care.

Department of Molecular Biology and Cell Pathology 3rd Faculty of Medicine Charles University Prague Czech Republic

Institute for the Care of the Mother and Child 3rd Faculty of Medicine Charles University Prague Czech Republic

See more in PubMed

Öztürk MA, Haznedaroğlu IC, Turgut M, Göker H. Current debates in antiphospholipid syndrome: the acquired antibody‐mediated thrombophilia. Clin Appl Thromb Hemost. 2004;10:89‐126. PubMed

El Hasbani G, Viola M, Sciascia S, Taher AT, Uthman I. Antiphospholipid antibodies in inflammatory and autoimmune rheumatic and musculoskeletal diseases beyond lupus: a systematic review of the available evidence. Rheumatol Ther. 2021;8:81‐94. PubMed PMC

Reinstein E, Shoenfeld Y. Antiphospholipid syndrome and cancer. Clin Rev Allergy Immunol. 2007;32:184‐187. PubMed

Asherson RA, Cervera R. Antiphospholipid antibodies and infections. Ann Rheum Dis. 2003;62:388‐393. PubMed PMC

Di Prima FA, Valenti O, Hyseni E, et al. Antiphospholipid syndrome during pregnancy: the state of the art. J Prenat Med. 2011;5:41‐53. PubMed PMC

Fredi M, Tincani A. Obsteric APS. In: Meroni P, ed. Antiphospholipid Antibody Syndrome. Rare Diseases of the Immune System. Springer International Publishing; 2015:233‐248.

Biggioggero M, Meroni PL. The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev. 2010;9:299‐304. PubMed

Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295‐306. PubMed

Barbhaiya M, Zuily S, Naden R, et al. 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Ann Rheum Dis. 2023;82:1258‐1270. PubMed

Alijotas‐Reig J, Esteve‐Valverde E, Ferrer‐Oliveras R, et al. The European registry on obstetric antiphospholipid syndrome (EUROAPS): a survey of 1000 consecutive cases. Autoimmun Rev. 2019;18:406‐414. PubMed

Yang J, Liang M. Risk factors for pregnancy morbidity in women with antiphospholipid syndrome. J Reprod Immunol. 2021;145:103315. PubMed

Cervera R, Serrano R, Pons‐Estel GJ, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10‐year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015;74:1011‐1018. PubMed

Bouvier S, Cochery‐Nouvellon E, Lavigne‐Lissalde G, et al. Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH‐APS observational study. Blood. 2014;123:404‐413. PubMed

Xi F, Cai Y, Lv M, et al. Anticardiolipin positivity is highly associated with intrauterine growth restriction in women with antiphospholipid syndrome. Clin Appl Thromb Hemost. 2020;26:1076029620974455. PubMed PMC

Appenzeller S, Souza FH, Wagner Silva de Souza A, Shoenfeld Y, de Carvalho JF. HELLP syndrome and its relationship with antiphospholipid syndrome and antiphospholipid antibodies. Semin Arthritis Rheum. 2011;41:517‐523. PubMed

Pécourt M, Yelnik C, Ghesquiere L, et al. Is the presence of antiphospholipid antibodies a poor prognostic factor for patients with hemolysis, elevated liver enzymes, and low platelet count syndrome? Am J Obstet Gynecol. 2021;225:432‐e1. PubMed

Mekinian A, Loire‐Berson P, Nicaise‐Roland P, et al. Outcomes and treatment of obstetrical antiphospholipid syndrome in women with low antiphospholipid antibody levels. J Reprod Immunol. 2012;94:222‐226. PubMed

Alijotas‐Reig J, Esteve‐Valverde E, Ferrer‐Oliveras R, et al. Comparative study of obstetric antiphospholipid syndrome (OAPS) and non‐criteria obstetric APS (NC‐OAPS): report of 1640 cases from the EUROAPS registry [published correction appears in Rheumatology (Oxford). 2021;60:5883]. Rheumatology. 2020;59:1306‐1314. PubMed

Pregnolato F, Gerosa M, Raimondo MG, et al. EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti‐phospholipid antibodies. Rheumatology. 2021;60:1114‐1124. PubMed

Ofer‐Shiber S, Molad Y. Frequency of vascular and pregnancy morbidity in patients with low vs. moderate‐to‐high titers of antiphospholipid antibodies. Blood Coagul Fibrinolysis. 2015;26:261‐266. PubMed

Foddai SG, Radin M, Cecchi I, et al. The prevalence of antiphospholipid antibodies in women with late pregnancy complications and low‐risk for chromosomal abnormalities. J Thromb Haemost. 2020;18:2921‐2928. PubMed

Gibbins KJ, Tebo AE, Nielsen SK, Branch DW. Antiphospholipid antibodies in women with severe preeclampsia and placental insufficiency: a case‐control study. Lupus. 2018;27:1903‐1910. PubMed PMC

Ferrer‐Oliveras R, Llurba E, Cabero‐Roura L, Alijotas‐Reig J. Prevalence and clinical usefulness of antiphospholipid and anticofactor antibodies in different Spanish preeclampsia subsets. Lupus. 2012;21:257‐263. PubMed

Abou‐Nassar K, Carrier M, Ramsay T, Rodger MA. The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta‐analysis. Thromb Res. 2011;128:77‐85. PubMed

Opatrny L, David M, Kahn SR, Shrier I, Rey E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheumatol. 2006;33:2214‐2221. PubMed

Silver RM, Parker CB, Reddy UM, et al. Antiphospholipid antibodies in stillbirth. Obstet Gynecol. 2013;122:641‐657. PubMed PMC

American College of Obstetricians and Gynecologists . Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222. Obstet Gynecol. 2020;135:237‐260. PubMed

Lees CC, Stampalija T, Baschat A, et al. ISUOG practice guidelines: diagnosis and management of small‐for‐gestational‐age fetus and fetal growth restriction. Ultrasound Obstet Gynecol. 2020;56:298‐312. PubMed

ACOG practice bulletin No. 190: gestational diabetes mellitus. Obstet Gynecol. 2018;131:49‐64. PubMed

Prelabor rupture of membranes: ACOG practice bulletin, number 217. Obstet Gynecol. 2020;135:80‐97. PubMed

ACOG practice bulletin no. 127: management of preterm labor. Obstet Gynecol. 2012;119(6):1308‐1317. PubMed

Prediction and prevention of spontaneous preterm birth: ACOG practice bulletin, number 234. Obstet Gynecol. 2021;138:65‐90. PubMed PMC

Management of Stillbirth: obstetric care consensus No. 10. Obstet Gynecol. 2020;135:110‐132. PubMed

Ünlü O, Zuily S, Erkan D. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur J Rheumatol. 2016;3:75‐84. PubMed PMC

Lu D, Song Z, Gao Y, Zhang J, Guo X. Patients with autoimmune thyroid diseases have higher prevalence of positive antiphospholipid antibodies: a systematic review and meta‐analysis. Int J Endocrinol. 2022;2022:8271951. PubMed PMC

Merashli M, Alves JD, Gentile F, Ames PRJ. Relevance of antiphospholipid antibodies in multiple sclerosis: a systematic review and meta analysis. Semin Arthritis Rheum. 2017;46:810‐818. PubMed

Sipeki N, Davida L, Palyu E, et al. Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease. World J Gastroenterol. 2015;21:6952‐6964. PubMed PMC

Laine O, Pitkänen K, Lindfors K, et al. Elevated serum antiphospholipid antibodies in adults with celiac disease. Dig Liver Dis. 2018;50:457‐461. PubMed

Juanola X, Mateo L, Domenech P, et al. Prevalence of antiphospholipid antibodies in patients with ankylosing spondylitis. J Rheumatol. 1995;22:1891‐1893. PubMed

Chighizola CB, de Jesus GR, Branch DW. The hidden world of anti‐phospholipid antibodies and female infertility: a literature appraisal. Autoimmun Rev. 2016;15:493‐500. PubMed

Huo Y, Xu Y, Wang J, et al. Analysis of the serum reproductive system related autoantibodies of infertility patients in Tianjin region of China. Int J Clin Exp Med. 2015;8:14048‐14053. PubMed PMC

Aguirre Del‐Pino R, Monahan RC, Huizinga TWJ, Eikenboom J, Steup‐Beekman GM. Risk factors for antiphospholipid antibodies and antiphospholipid syndrome. Semin Thromb Hemost. 2024;50:817‐828. PubMed

Helgadottir LB, Skjeldestad FE, Jacobsen AF, Sandset PM, Jacobsen EM. The association of antiphospholipid antibodies with intrauterine fetal death: a case‐control study. Thromb Res. 2012;130:32‐37. PubMed

Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101:1827‐1832. PubMed

Del Ross T, Ruffatti A, Cuffaro S, et al. The clinical relevance of the IgM isotype of antiphospholipid antibodies in the vascular antiphospholipid syndrome. Thromb Res. 2015;136:883‐886. PubMed

Kelchtermans H, Pelkmans L, de Laat B, Devreese KM. IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis. J Thromb Haemost. 2016;14:1530‐1548. PubMed

Chayoua W, Kelchtermans H, Gris JC, et al. The (non‐)sense of detecting anti‐cardiolipin and anti‐β2glycoprotein I IgM antibodies in the antiphospholipid syndrome. J Thromb Haemost. 2020;18:169‐179. PubMed

Yang R, Zhang J, Zhang L, Liu Y, Guo Q. Combined detection of anticardiolipin and anti‐β2‐glycoprotein 1 antibodies may predict pregnancy outcome. Am J Transl Res. 2022;14:1750‐1756. PubMed PMC

Yasuda M, Takakuwa K, Tokunaga A, Tanaka K. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet Gynecol. 1995;86:555‐559. PubMed

Yamada H, Atsumi T, Kobashi G, et al. Antiphospholipid antibodies increase the risk of pregnancy‐induced hypertension and adverse pregnancy outcomes. J Reprod Immunol. 2009;79:188‐195. PubMed

Devreese KM. Standardization of antiphospholipid antibody assays. Where do we stand? Lupus. 2012;21:718‐721. PubMed

Viall CA, Chamley LW. Histopathology in the placentae of women with antiphospholipid antibodies: a systematic review of the literature. Autoimmun Rev. 2015;14:446‐471. PubMed

D'Ippolito S, Ticconi C, Tersigni C, et al. The pathogenic role of autoantibodies in recurrent pregnancy loss. Am J Reprod Immunol. 2020;83:e13200. PubMed

Mineo C, Shaul PW, Bermas BL. The pathogenesis of obstetric APS: a 2023 update. Clin Immunol. 2023;255:109745. PubMed PMC

Di Simone N, Caliandro D, Castellani R, Ferrazzani S, Caruso A. Interleukin‐3 and human trophoblast: in vitro explanations for the effect of interleukin in patients with antiphospholipid antibody syndrome. Fertil Steril. 2000;73:1194‐1200. PubMed

Marder W, Knight JS, Kaplan MJ, et al. Placental histology and neutrophil extracellular traps in lupus and pre‐eclampsia pregnancies. Lupus Sci Med. 2016;3:e000134. PubMed PMC

Yelnik CM, Porter TF, Branch DW, et al. Brief report: changes in antiphospholipid antibody titers during pregnancy: effects on pregnancy outcomes. Arthritis Rheumatol. 2016;68:1964‐1969. PubMed PMC

Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2020;72:529‐556. PubMed

Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78:1296‐1304. PubMed PMC

Lockwood CJ, Lockshin MD. Antiphospholipid syndrome: Obstetric implications and management in pregnancy. Accessed May 20, 2024. https://www.uptodate.com/contents/antiphospholipid‐syndrome‐obstetric‐implications‐and‐management‐in‐pregnancy

Poon LC, Shennan A, Hyett JA, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre‐eclampsia: a pragmatic guide for first‐trimester screening and prevention. Int J Gynaecol Obstet. 2019;145(Suppl 1):1‐33. PubMed PMC

National Institute for Health and Care Excellence . Hypertension in pregnancy: diagnosis and management (NICE guideline NG133). Accessed January 9, 2025. https://www.nice.org.uk/guidance/ng133